Mark McDade's Disposal of Tourmaline Bio Shares and Stock Options

Mark McDade, a director of Tourmaline Bio, Inc., disposed of all his shares and stock options in the company on October 28, 2025, as part of a merger agreement with Novartis AG. The merger involved a cash tender offer of $48.00 per share, resulting in the disposal of 518 directly held shares and 741,691 indirectly held shares through Qiming U.S. Healthcare Funds. Additionally, 46,800 stock options were canceled and converted into cash. The transactions were executed pursuant to the merger agreement, which was finalized on the same date.